Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2026-06-08 16:17:44 ET · period of report 2026-06-04 · accession 0001193125-26-261782 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 16:17 | 2026-06-04 | VNDA | Honore Tage | Dir | A - Grant | $0.00 | +41.6K | 135.1K | +45% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-04 | A | A | 41,600 | $0.00 | 135,069 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |